Boston, MA 02/25/2013 (wallstreetpr) – Roche Holding Ltd (VTX: ROG) in partnership with ImmunoGen, Inc (NASDAQ:IMGN has created an anti-cancer therapy that has gained approval from the U.S Food Drug Administration. The drug which was originally called T-DM1 will now be sold under the brand name Kadcyla as it has received clearance for treating humans who suffer from Her2(positive metastatic breast cancer). The therapy is a combination of the anti-cancer drug manufactured by Roche Holding Ltd (VTX: ROG) and technology from ImmunoGen, Inc (NASDAQ:IMGN)’s.
Killing cancer cells and boosting company growth
This therapy ensures that the drug bypasses healthy cells and carries the chemotherapy straight to the malignant ones. ImmunoGen, Inc (NASDAQ:IMGN) announced that its U.S approval will earn it $10.5 million. According to a market analyst, this high-potential drug is expected to generate over $5 billion of worldwide sales. Sandra Horning, head of global oncology at the Switzerland-based Roche Holding Ltd (VTX: ROG) said that the therapy is a super-Herceptin of sorts. Another important plus is that the drug has fewer side-effects when compared to other existing therapies.
Herceptin before Kadcyla
Kadcyla will be launched in the U.S within a fortnight but the FDA has said that patients should first try Herceptin treatment before moving onto Kadcyla, both of which are Roche Holding Ltd (VTX:ROG) products. The cost of the Kadcyla treatment will amount to $9800 per month and will have to continue for 9.6 months taking its cost to $94,000 for the entire course. Roche Holding Ltd (VTX: ROG), the worlds largest manufacturer of tumor medication is testing the same drug as a first-line treatment for women who suffer from spreading (metastatic) breast cancer. ImmunoGen, Inc (NASDAQ:IMGN) will be receiving between 3 percent- 7 percent in royalties and its worldwide collections from royalties could be to the tune of $350 million by 2025. T-DM1 prevents the growth of new cancer cells and the DM1 release destroys them and the approval of this drug has opened up a host of possibilities in the treatment of cancer.
Shares of ImmunoGen, Inc (NASDAQ:IMGN) went up by 1.89% to close at $14.57
For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com
